Pharma industry groups are sounding the alarm, warning that President Donald Trump’s tariffs could worsen drug shortages, ...

Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Tech entrepreneur and longevity advocate Bryan Johnson has discontinued his use of rapamycin, a controversial anti-ageing ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

drug prices, and what’s ahead for Johnson & Johnson. This interview has been condensed and edited for clarity. You've had some structural changes and spun out the consumer business. Has that ...

B Health and two safety-net hospitals want to help the government prove that drugmakers are required to give upfront ...

Tim Speers is alleged to have had spray paint at the Gloucestershire estate the day before Boris Johnson's wedding party ...